1. Scrip
  2. >>Archive

Vertex unveils promising VX-222/Incivek combo data in HCV

 
• By Mike Ward

Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (scripintelligence.com, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.

Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (scripintelligence.com, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.

Interim data from the ongoing ZENITH Phase II study looking at the safety, tolerability and efficacy of VX-222, its lead hepatitisC virus polymerase inhibitor, with Incivek, Pegasys (pegylated alpha interferon)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.